New hope for myasthenia gravis: early ravulizumab treatment under study

NCT ID NCT06967480

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 21 times

Summary

This study tests whether the drug ravulizumab can improve daily activities in people with early-stage generalized myasthenia gravis who have a specific antibody (AChR+). About 40 participants will receive treatment and be followed for 50 weeks. The goal is to see if starting treatment early helps control symptoms and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Trial Site

    RECRUITING

    Bergamo, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Bologna, Italy

  • Clinical Trial Site

    RECRUITING

    Bologna, Italy

  • Clinical Trial Site

    RECRUITING

    Brescia, Italy

  • Clinical Trial Site

    RECRUITING

    Florence, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Imperia, Italy

  • Clinical Trial Site

    RECRUITING

    Lecco, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Messina, Italy

  • Clinical Trial Site

    RECRUITING

    Milan, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Milan, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Naples, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Novara, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Orbassano, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Padova, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Palermo, Italy

  • Clinical Trial Site

    RECRUITING

    Parma, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Pavia, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Pisa, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Roma, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Salerno, Italy

  • Clinical Trial Site

    RECRUITING

    San Giovanni Rotondo, 71013, Italy

  • Clinical Trial Site

    RECRUITING

    Sassari, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Torino, Italy

Conditions

Explore the condition pages connected to this study.